BioNotebook: ImmunoGen, Seattle Genetics, Keryx, OncoMed
This article was originally published in Scrip
Executive Summary
ImmunoGen sinks on Phase II ADC failure; Seattle Genetics revenue grows; Keryx rises on Phase II data; and OncoMed earns $15m milestone.